ARTICLE | Clinical News
Antisoma dropping AS1402
August 7, 2009 11:42 PM UTC
Antisoma plc (LSE:ASM) discontinued development of AS1402 based on results from a Phase II trial to treat locally advanced or metastatic breast cancer. The company said the study of the humanized mAb ...